NZ628407A - Treatment of cancer with tor kinase inhibitors - Google Patents

Treatment of cancer with tor kinase inhibitors

Info

Publication number
NZ628407A
NZ628407A NZ628407A NZ62840713A NZ628407A NZ 628407 A NZ628407 A NZ 628407A NZ 628407 A NZ628407 A NZ 628407A NZ 62840713 A NZ62840713 A NZ 62840713A NZ 628407 A NZ628407 A NZ 628407A
Authority
NZ
New Zealand
Prior art keywords
breast cancer
tor kinase
cancer
treatment
kinase inhibitors
Prior art date
Application number
NZ628407A
Other languages
English (en)
Inventor
Shuichan Xu
Kristen Mae Hege
Heather Raymon
Rama K Narla
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of NZ628407A publication Critical patent/NZ628407A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ628407A 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors NZ628407A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611374P 2012-03-15 2012-03-15
US201261715331P 2012-10-18 2012-10-18
PCT/US2013/031185 WO2013138553A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (1)

Publication Number Publication Date
NZ628407A true NZ628407A (en) 2016-04-29

Family

ID=48014333

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628407A NZ628407A (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Country Status (19)

Country Link
US (2) US20130245027A1 (cg-RX-API-DMAC7.html)
EP (1) EP2825169B1 (cg-RX-API-DMAC7.html)
JP (2) JP2015511963A (cg-RX-API-DMAC7.html)
KR (1) KR102057359B1 (cg-RX-API-DMAC7.html)
CN (1) CN104271139A (cg-RX-API-DMAC7.html)
AU (1) AU2013202993B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014022707A2 (cg-RX-API-DMAC7.html)
CA (1) CA2867348A1 (cg-RX-API-DMAC7.html)
ES (1) ES2678250T3 (cg-RX-API-DMAC7.html)
IL (1) IL234641B (cg-RX-API-DMAC7.html)
MX (1) MX360880B (cg-RX-API-DMAC7.html)
MY (1) MY178012A (cg-RX-API-DMAC7.html)
NI (1) NI201400112A (cg-RX-API-DMAC7.html)
NZ (1) NZ628407A (cg-RX-API-DMAC7.html)
PH (1) PH12014502046B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201405724RA (cg-RX-API-DMAC7.html)
TW (1) TWI635862B (cg-RX-API-DMAC7.html)
WO (1) WO2013138553A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201406701B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
CN112933088B (zh) * 2021-02-03 2022-02-22 南华大学附属第一医院 Y041-5921在制备抗肿瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
RU2474582C2 (ru) 2006-10-19 2013-02-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы
CA2721072A1 (en) * 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of gleditsia sinensis lam
WO2010022243A1 (en) * 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds

Also Published As

Publication number Publication date
SG11201405724RA (en) 2014-10-30
US20130245027A1 (en) 2013-09-19
KR20140138951A (ko) 2014-12-04
NI201400112A (es) 2015-01-15
WO2013138553A1 (en) 2013-09-19
JP6470820B2 (ja) 2019-02-13
PH12014502046A1 (en) 2014-12-10
BR112014022707A2 (pt) 2020-10-27
KR102057359B1 (ko) 2019-12-18
IL234641A0 (en) 2014-11-30
IL234641B (en) 2020-04-30
JP2015511963A (ja) 2015-04-23
ES2678250T3 (es) 2018-08-09
EP2825169A1 (en) 2015-01-21
MX360880B (es) 2018-11-21
MX2014011118A (es) 2015-04-08
JP2018052963A (ja) 2018-04-05
ZA201406701B (en) 2016-05-25
TWI635862B (zh) 2018-09-21
PH12014502046B1 (en) 2020-10-16
CA2867348A1 (en) 2013-09-19
AU2013202993A1 (en) 2013-10-03
MY178012A (en) 2020-09-29
TW201343165A (zh) 2013-11-01
CN104271139A (zh) 2015-01-07
US20230338370A1 (en) 2023-10-26
AU2013202993B2 (en) 2015-09-03
EP2825169B1 (en) 2018-05-09
HK1201753A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
NZ628421A (en) Treatment of cancer with tor kinase inhibitors
NZ628420A (en) Treatment of cancer with tor kinase inhibitors
NZ628416A (en) Treatment of cancer with tor kinase inhibitors
IL281180B (en) 1-ethyl-7-(2-methyl-6-(4h-4,2,1-triazol-3-yl)pyridin-3-yl)-4,3-dihydropyrazino[3,2-b]pyrazine-2 (1h)-one for cancer treatment
UA110697C2 (uk) ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK
PL3808749T3 (pl) Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
UA117590C2 (uk) ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
PH12014502046B1 (en) Treatment of cancer with tor kinase inhibitors
PH12018501137B1 (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
MX350112B (es) Derivados de furo[3,2-b]- y tieno[3,2-b]piridina como inhibidores de tbk1 e ikk.
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
IL241950B (en) Compound 1-ethyl-7-(2-methyl-6-(1h-4,2,1-triazol-3-yl)pyridin-3-yl)-4,3-dihydropyrazino[2,3-b]pyrazine- 2(1h)-ven for the treatment of glioblastoma multiforme
PH12013501952A1 (en) Thieno [2, 3 -d] pyrimidine derivatives and their use to treat arrhythmia
NZ714742A (en) Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
NZ629459A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
PH12018501490A1 (en) Use of inhibitors of the activity or function of pi3k for the treatment of primary sj™gren's syndrome
NZ717887A (en) Treatment of cancer with tor kinase inhibitors
TH165140A (th) การรักษามะเร็งด้วยตัวยับยั้ง tor ไคเนส
TN2013000231A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
UA65248U (ru) Способ лечения острых очаговых поражений головного мозга у потерпевших с травматической болезнью

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180220

LAPS Patent lapsed